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during 2 weeks of treatment and at the ﬁnal examination 1 week
after the last hyperthermia relative to the baseline value of 9.55 points.
The mean absolute score reductions reaches 3.55 points at the ﬁnal
examination. JOA scale improved signiﬁcantly over time, reaching 86.25
points at the ﬁnal examination from the baseline average score of 67.5
points. Five joints (62%) reached 95 points or more and almost all of
the symptoms were eradicated. During the study, no side effects such as
an exacerbation of swelling, burning, or paraesthesia were observed to
result from exposure to the radiofrequency.
Conclusions: The primary goals of contemporary therapy for OA are to
reduce pain, improve joint function and improve quality of life because
there is no structure modifying therapy for OA that has gained consensus
at this point. In animal studies, the expression of proteoglycan and type
II collagen in the articular cartilage signiﬁcantly increases at a level
in which the temperature inside the joint increased to approximately
40°C. Moreover, heat shock protein 70 (HSP 70) was accumulated in
chondrocyte when the articular cartilage was heated to 40°C in vivo. HSP
70 provides effects to inhibit apoptosis of chondrocytes and to accelerate
the proteoglycan metabolism. In this study, radiofrequency hyperthermia
safely increases the temperature inside the knee joint. Radiofrequency
on OA knee provides a remarkable pain relief effect and can improve the
patients’ daily life. In the future, clinical studies should be performed
with a protocol containing more cases along with appropriate control
groups.
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HIGH-MOLECULAR-WEIGHT HYALURONAN (EUFLEXXA®) FOR
THE TREATMENT OF CHRONIC SHOULDER PAIN ASSOCIATED WITH
GLENOHUMERAL ARTHRITIS
A.J. Weil. Non-Surgical Orthopaedics, P.C., Atlanta, GA, USA
Purpose: There is insufﬁcient evidence to determine whether intra-
articular (IA) injections may be effective for treatment of glenohumeral
osteoarthritis (OA). Euﬂexxa, a high molecular weight hyaluronan (1%
sodium hyaluronate; HMWHA), has been shown to be a safe and effective
treatment for patients with knee OA. There is also support for the use of
HA injection for the treatment of chronic shoulder pain associated with
OA or rotator cuff damage. This study was conducted to evaluate the
safety and efﬁcacy of HMW HA for the treatment of chronic shoulder
pain associated with osteoarthritis (OA).
Methods: Subjects with glenohumoral OA and chronic pain (n =27)
received 3 weekly injections of HMW HA and were assessed for changes
in pain (100mm visual analog scale [VAS]), range of motion, and the
subject’s and physician’s global assessment over 26 weeks. Subjects
were also assessed for pain, stiffness, and physical functioning using the
Western Ontario and McMaster Universities Arthritis Index (WOMAC).
Finally, responses were evaluated using modiﬁed Outcome Measures in
Rheumatoid Arthritis Clinical Trials (OMERACT) – Osteoarthritis Research
Society International (OARSI) Proposition D Criteria. Safety was assessed
by recording adverse events (AEs).
Results: HMW HA signiﬁcantly improved pain (VAS, WOMAC), range
of motion, stiffness, and physical functioning scores. 77.8% of subjects
were rated as having an OMERACT-OARSI Proposition D high response.
There were no serious AEs and no AEs were considered to be related to
treatment.
Conclusions: HMW HA should be considered as a treatment option
for patients with symptomatic shoulder OA after traditional nonsurgical
treatment options have failed.
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PATIENTS WITH KNEE OSTEOARTHRITIS DEMONSTRATE IMPROVED
GAIT AND CLINICAL SYMPTOMS FOLLOWING A NON-INVASIVE
BIOMECHANICAL THERAPY
R. Lador1, G. Segal2, Y. Kosashvili3, M. Drexler1, O. Chechik1, A. Haim1,
M. Salai1, R. Debi4, A. Elbaz2. 1Sourasky Med. Ctr., Tel-Aviv, Israel;
2AposTherapy Res. Group, Herzliya, Israel; 3Assaf Harofeh Med. Ctr., Zeriﬁn,
Israel; 4Barzilay Med. Ctr., Ashkelon, Israel
Purpose: Biomechanical interventions for the management of knee
osteoarthritis (OA) are emerging. AposTherapy is one type of
biomechanical therapy that was shown to reduce knee adduction
moment and improve gait patterns and clinical symptoms. The purpose
of the current study was to further investigate the changes in gait
patterns following AposTherapy and to deﬁne the possible clinical
beneﬁts of the therapy for patients with knee OA.
Methods: 412 patients with knee OA were evaluated using a
computerized gait test as well as with the Western Ontario and
McMaster Osteoarthritis Index (WOMAC) and SF-36 Health Survey self-
evaluation questionnaires. Following these measurements, the Apos
system was individually calibrated to each patient according to his or
her gait patterns and clinical evaluation. Patients then received exercise
guidelines and underwent AposTherapy. A second evaluation of gait and
clinical symptoms was conducted after three months of therapy.
Results: After three months of therapy, a signiﬁcant improvement was
found in all gait parameters (all p< 0.01), as well as in the level of pain,
function and quality of life (all p < 0.01). High correlations were found
between the improvement in gait parameters and the improvement in
self-evaluation questionnaires.
Conclusions: AposTherapy led to a signiﬁcant reduction in pain and
improvement in function, quality of life and gait patterns. These ﬁnding
support previous ﬁndings and deepens the understanding of this new
non-invasive biomechanical therapy in patients with knee OA.
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EFFECTS OF LOW POWER LASER THERAPY ON ARTICULAR CARTILAGE
BIOMECHANICS IN AN EXPERIMENTAL MODEL OF OSTEOARTHRITIS
Z.S. Rezaeian1, G. Torkaman1, A. Esteki2, A. Sabbaghian3, R. Ravanbod4.
1Tarbiat Modares Univ., Tehran, Iran, Islamic Republic of ; 2Shahid Beheshti
Univ., Tehran, Iran, Islamic Republic of ; 3Akhtar Hosp., Tehran, Iran, Islamic
Republic of ; 4Hemophilia Comprehensive Treatment Ctr., Tehran, Iran,
Islamic Republic of
Purpose: Articular cartilage is a specialized connective tissue covering
articular surface in synovial joints. According to the position of cartilage
in these joints, any motion results in different compressive and shear
loading on cartilage; cartilage healing is too slow. In abnormal situations,
cartilage wear and tear can precede regeneration resulting in cartilage
degeneration phenomenon known as oseteoarthritis (OA).
Variety of researches is running to identify OA characteristics and
compare the quality and duration of the effects of therapeutic strategies.
On the other hand, experimental models using laboratory animales
are especially There are different animal models to study OA however
anterior cruciate ligament transaction (ACLT) is more common.
Low Power Laser Therapy (LPLT) is one of the common physical
modalities to relief pain. OA results in structural and functional changes
in cartilage. The question is wheater LPLT can affect cartilage function
or not? Present study focused on the short-term effects of LPLT on the
bimoechanical properties of articular cartilage as an index of cartilage
function in rabbit ACLT model.
Methods: Total of 15 male white skeletally mature Dutch rabbits
weighting 1.5 to 2 kg devided into 3 groups (85 Control, 85 Surgery
and Laser). The anterior cruciate ligament (ACL) was cut in the left knee
of rabbits in 85 Surgery and Laser groups. The rabbits were housed
seperatedly in cages where they can move easily and have free access to
food and water. 85 days (3 months) following the surgery theses rabbit
were sacriﬁced. 85 Control group underwent no intervention during the
same period.
LPLT started at the 62th day after surgery for 10 sessions, 3 days a week
using Ga-Al-As pulse 810nm Laser (Physiolaser, RJ Laser, Germany).
For biomechanical test, tibia and femur seperated and prepared for
thickness measurement and stress-relaxation test by Zwick Universal
Testing Machine; Zwick/Roell GmbH & Co., Ulm, Germany.
Kruskal Wallis test used to detect any difference between groups with
alpha = 0.05 and Beta = 0.95. To determine which two groups were
signiﬁcantly different the Mann-Withney test was used.
Results: Cartilage thickness of tibia and femur was not different while
comparing groups (Table 1). On the other hand, signiﬁcant differences
between tibial cartilages were observed in different groups as shown
in Figure 1. Maximal force in 85 control group was signiﬁcantly less
than 85 surgery and laser groups (P = 0.014 and P=0.043 respectively).
Same differences were detected in Young modulus (P = 0.014, P = 0.043
respectively).
The ACL is one of the four major knee ligaments. The injured ACL cannot
control knee movement especially tibial anterior glide therefore, knee
bones rub against each other in an abnormal way. The induced abnormal
sliding can damage the cartilage, menisci and even other ligaments
around the knee and eventually results in OA.
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ACLT changes the biomechanical properties of articular cartilage more
than cartilage thickness although it seems that three months after ACLT,
cartilage thickness is less than control group. On the other hand, in
both femur and tibia cartilage seems to become thicker following LPLT;
however, none of these changes is statictically signiﬁcant.
Apparently, destructive effects of ACLT are more pronounced on tibial
cartilage. 12 weeks after ACLT, tibial cartilage strength and young
modulus decreased signiﬁcantly, although 10 seassions of LPT reversed
this process completely. Same trend was observed in femural cartilage
but these changes were not statistically signiﬁcant.
Conclusions: Following ACLT articular cartilage softens and its strength
decreases. It seems that therapeutic laser can help cartilage to resume
its original characteristics.
Table 1.
Fig. 1.
Therapy – Pharmacologic
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MODULATING MAPK SIGNALING CAN ATTENUATE THE SEVERITY
OF OSTEOARTHRITIS
Y. Xiao, I. Prasadam, R. Crawford. Queensland Univ. of Technology,
Brisbane, Australia
Purpose: Osteoarthritis (OA) is the most common musculoskeletal
disorder and represents a major health burden to society. OA is associated
with the irreversible degeneration of articular cartilage. Notably, in
this condition, articular cartilage chondrocytes undergo phenotypic and
gene expression changes that are reminiscent of their hypertrophic
differentiation in the growth plate during skeletal development. Also, the
adjacent subchondral bone shows signs of abnormal mineral density and
enhanced production of bone turnover markers, indicative of osteoblast
dysfunction. Our previous study ﬁndings suggest that Extracellular
signal-regulated kinases (ERK) signaling is activated in both in OA
subchondral bone and cartilage. The present study is a follow up of
our previous ﬁndings to identify whether the pharmacological inhibition
ERK signaling pathway slows down the progression of OA.
Methods: We developed three different types of OA rat models:
Menisectomy (MSX) induced OA, Anterior cruciate ligament transaction
(ACLT) induced OA and Mono-ido-acetate (MIA) induced OA to test
whether U0126, a MAPK-ERK1/2 pathway inhibitor shows any protective
effects towards OA cartilage degeneration and subchondral bone changes.
The cause of disease occurrence is different in the above models;
therefore the obtained data will show how the drug is acting in different
types of OA conditions. From day 7 post-surgery treatment groups were
given an intra-articular injection of ERK1/2 inhibitor (UO126) every
2 days at a concentration of 0.5 mM in 50ml using 30G needle for
8 weeks. The control group received same volume of vehicle alone
(saline+ DMSO) without administration drug. At the end of each time
point rats were euthanized and knee joints were parafﬁn embedded.
Serial 5mm sections obtained at 100mm intervals from the non weight
bearing region and weight-bearing region of each knee joint were
stained with safranin O-fast green, Type 10 collagen (COL10), runt-related
transcription factor-2 (RUNX2) and a disintegrin and metalloproteinase
with thrombospondin type 1 motif-5 (ADAMTS5). OA severity in the
tibial plateau was evaluated according to Mankin’s histologic grading
system (Mankin’s score: 0 to 14), and a cartilage destruction score
was assigned for each knee sample (n =10). Micro-Ct was performed
to see the protective effects of U0126 on subchondral bone. Cartilage
and subchondral bone tissue lysate was extracted from drug treated vs.
untreated animals and western blotting technique was applied to see
the molecular differences.
Results: pERK-1/2 was signiﬁcantly increased in the cartilage and
subchondral bone of all three OA models compared to sham conﬁrming
the pathological relevance of this signaling pathway in OA. U0126 down
regulated the pERK-1/2 expression in treatment group conﬁrming the
efﬁcacy of U0126 in inhibiting ERK at in vivo level. Furthermore, U0126
treated animal models showed signiﬁcantly reduced Mankin score (up
to 40–50%), less proteoglycan depletion, decreased expression of COL0,
RUNX2 and ADAMTS5 proteins in all three OA models compared to
untreated controls (Figure 1). OA knees showed increase in BV and BV/TV
compared to shams at week 8. The increased BV and BV/TV were partially
reversed when the animals were treated with the U0126, indicating the
therapeutic beneﬁts of U0126 on OA subchondral bone changes.
Conclusions: Together, these ﬁndings raise the possibility that ERK
blockade can be used as a therapeutic approach to inhibit OA articular
cartilage degeneration and subchondral bone changes.
Fig. 1.
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SINGLE ORAL DOSE OF (1200 MG) SACHET OF CHONDROITIN 4&6
SULFATE (CS4&6 – CHONDROSULF®) RELIEVES PAIN AND IMPROVES
FUNCTION. RESULTS OF A DOUBLE BLIND STUDY, VERSUS PLACEBO
AND AN ACTIVE TREATMENT IN KNEE OA PATIENTS
J. Reginster1, E. Tajana2. 1Univ. of Lie`ge, Lie`ge 1, Belgium; 2IBSA – Inst.
Biochimique SA, Pambio-Noranco, Switzerland
Objective: Efﬁcacy, safety and tolerability evaluation of a single oral dose,
1200mg sachet of chondroitin 4&6 sulfate (Chondrosulf® 1200) versus
placebo (superiority study) and versus 3 daily capsules of chondroitin
4&6 sulfate 400mg (Chondrosulf®400), during 91 days, in patients with
knee OA (non inferiority study).
Methods: Comparative, double-blind, randomized, multicenter study, in
parallel groups, including 353 patients of both genders, over 45 years,
with knee OA for at least 6 months. Minimum inclusion criteria was a
